--- title: "Talphera (TLPH) news: reverse split and offering" url: "https://aibio.space/companies/talphera/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TLPH reverse split and offering news: Talphera gets second 180-day Nasdaq bid price period, to December 1, 2025. Talphera, Inc." --- TLPH Talphera, Inc. NASDAQ · United States # Talphera (TLPH) news TLPH reverse split and offering news Financings · 2026-03-16 ## [Talphera closes third private placement tranche for approximately $4.1 million in gross proceeds](https://aibio.space/news/talphera-closes-third-private-placement-tranche-approximately-4-1/) Talphera (Nasdaq: TLPH) sold 639,931 shares at $0.586 and pre-funded warrants for up to 6,399,316 shares on March 13, 2026, to purchasers who did not join the earlier Optional Closing. ## Latest Talphera news 1. 2025-09-10 Financings [Talphera raises about $17 million in private placement with CorMedix and investors](https://aibio.space/news/talphera-raises-about-17-million-private-placement-cormedix-investors/) Shares sold at $0.55 each. Investors other than CorMedix agreed to buy about $12 million more if the NEPHRO CRRT study meets its primary endpoint and the stock clears a price test. 2. 2025-06-05 Listings [Talphera gets second 180-day Nasdaq bid price period, to December 1, 2025](https://aibio.space/news/talphera-gets-second-180-day-nasdaq-bid-price-period-december-1-2025/) Talphera (TLPH) moved its listing to The Nasdaq Capital Market on May 30, 2025 and received an additional 180 days to regain the $1.00 minimum bid price. It has told Nasdaq it will use a reverse stock split, if necessary. 3. 2025-06-05 Listings [Talphera gets second 180-day Nasdaq period, until December 1, 2025, to fix bid price](https://aibio.space/news/talphera-gets-second-180-day-nasdaq-period-until-december-1-2025-fix/) Talphera moved its stock to the Nasdaq Capital Market on May 30, 2025 to qualify. It told Nasdaq it would do a reverse stock split if necessary. ## Talphera at a glance - **Ticker**: TLPH - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $17.1 million ### Related companies - [Tempest Therapeutics](https://aibio.space/companies/tempest-therapeutics/) NASDAQ: TPST - [Rezolute](https://aibio.space/companies/rezolute/) NASDAQ: RZLT - [Protagonist Therapeutics](https://aibio.space/companies/protagonist-therapeutics/) NASDAQ: PTGX - [ACADIA Pharmaceuticals](https://aibio.space/companies/acadia-pharmaceuticals/) NASDAQ: ACAD - [Keros Therapeutics](https://aibio.space/companies/keros-therapeutics/) NASDAQ: KROS - [Trevena](https://aibio.space/companies/trevena/) OTC: TRVN - [Ligand Pharmaceuticals](https://aibio.space/companies/ligand-pharmaceuticals/) NASDAQ: LGND - [Xilio Therapeutics](https://aibio.space/companies/xilio-therapeutics/) NASDAQ: XLO ### Also on NASDAQ - [Stoke Therapeutics](https://aibio.space/companies/stoke-therapeutics/) STOK - [Ionis Pharmaceuticals](https://aibio.space/companies/ionis-pharmaceuticals/) IONS - [Aquestive Therapeutics](https://aibio.space/companies/aquestive-therapeutics/) AQST - [Iovance Biotherapeutics](https://aibio.space/companies/iovance-biotherapeutics/) IOVA - [NeuroSense Therapeutics](https://aibio.space/companies/neurosense-therapeutics/) NRSN - [Niki BioSolutions](https://aibio.space/companies/niki-biosolutions/) NIKI ## Talphera annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$6.0 million](https://www.sec.gov/Archives/edgar/data/1427925/000143774926009387/) | [$6.7 million](https://www.sec.gov/Archives/edgar/data/1427925/000143774926009387/) | | Net income (loss) | [-$14.3 million](https://www.sec.gov/Archives/edgar/data/1427925/000143774926009387/) | [-$13.0 million](https://www.sec.gov/Archives/edgar/data/1427925/000143774926009387/) | | Cash from operations | [-$11.4 million](https://www.sec.gov/Archives/edgar/data/1427925/000143774926009387/) | [-$12.7 million](https://www.sec.gov/Archives/edgar/data/1427925/000143774926009387/) | | Cash and equivalents | [$5.9 million](https://www.sec.gov/Archives/edgar/data/1427925/000143774926027316/) | [$8.9 million](https://www.sec.gov/Archives/edgar/data/1427925/000143774926009387/) | | Short-term investments | [$14.5 million](https://www.sec.gov/Archives/edgar/data/1427925/000143774926027316/) | [$0](https://www.sec.gov/Archives/edgar/data/1427925/000143774926009387/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $742,000, plus short-term investments of $16.3 million, $17.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Talphera Did Talphera do a reverse stock split? Our latest story on this, dated Jun 5, 2025: "Talphera gets second 180-day Nasdaq bid price period, to December 1, 2025". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/talphera-gets-second-180-day-nasdaq-bid-price-period-december-1-2025/). Has Talphera raised money recently? Our latest story on this, dated Mar 16, 2026: "Talphera closes third private placement tranche for approximately $4.1 million in gross proceeds". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/talphera-closes-third-private-placement-tranche-approximately-4-1/). What is the ticker symbol of Talphera? Talphera, Inc. trades under the ticker TLPH on NASDAQ. Where is Talphera listed? Talphera, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:R5XA; LSX:A3DWPN. What is the SEC CIK of Talphera? The SEC Central Index Key (CIK) for Talphera, Inc. is 1427925. Its filings are on SEC EDGAR. How many shares does Talphera have outstanding? 51,905,796 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Talphera listed under? Our directory records Talphera, Inc. under United States. What does Talphera do? Our directory classifies Talphera, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Talphera? The ISIN recorded for Talphera, Inc. is US00444T2096. Does aibio.space cover Talphera? aibio.space lists Talphera, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Talphera incorporated? SEC records list its state or country of incorporation as DE. Is Talphera profitable? Talphera, Inc. reported a net loss of $14.3 million for the fiscal year ended Dec 31, 2025, and used $11.4 million of cash in operations, per its annual report to the SEC. How much does Talphera spend on research and development? $6.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Talphera have? $17.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Talphera (TLPH) stock news? Our latest story on Talphera, dated Mar 16, 2026: "Talphera closes third private placement tranche for approximately $4.1 million in gross proceeds". Talphera (Nasdaq: TLPH) sold 639,931 shares at $0.586 and pre-funded warrants for up to 6,399,316 shares on March 13, 2026, to purchasers who did not join the earlier Optional Closing. [Source](https://aibio.space/news/talphera-closes-third-private-placement-tranche-approximately-4-1/). ## Investor discussion: Talphera Members talk about Talphera (TLPH). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Talphera, newest first. Each line links the filing it comes from. 1. 2026-03-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1427925/000143774926008217/acrx20260313_8k.htm) 2. 2025-10-24 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1427925/000143774925031731/acrx20251023_8k.htm) 3. 2025-09-29 Financings Filed a final prospectus for a securities offering. SEC Form 424B7. [Source](https://www.sec.gov/Archives/edgar/data/1427925/000143774925030045/acrx20250926_424b7.htm) 4. 2025-09-10 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1427925/000143774925028787/acrx20250909_8k.htm) 5. 2025-09-09 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1427925/000143774925028683/acrx20250906_def14a.htm) 6. 2025-08-29 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1427925/000143774925027994/acrx20250826c_pre14a.htm) 7. 2025-06-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1427925/000143774925019574/acrx20250605_8k.htm) 8. 2024-12-11 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1427925/000143774924037242/acrx20241210_8k.htm) 9. 2024-11-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1427925/000143774924036376/acrx20241129_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TLPH on TradingView](https://www.tradingview.com/symbols/NASDAQ-TLPH/). ## SEC filings and registration - **SEC name**: Talphera, Inc. - **CIK**: 1427925 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: TLPH (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 1850 GATEWAY DRIVE, SAN MATEO, CA, 94404 - **Phone**: 650-216-3500 - **Shares outstanding**: 51,905,796 as of 2026-08-06 (10-Q filed 2026-08-12) - **Former names**: ACELRX PHARMACEUTICALS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1427925/000143774926027316/acrx20260630_10q.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1427925/000143774926027311/acrx20260811_8k.htm) filed 2026-08-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1427925/000143774926021446/acrx20260622_8k.htm) filed 2026-06-23 - [10-Q](https://www.sec.gov/Archives/edgar/data/1427925/000143774926016748/acrx20260331_10q.htm) filed 2026-05-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1427925/000143774926016724/acrx20260511_8k.htm) filed 2026-05-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1427925/000143774926013895/acrx20260422_def14a.htm) filed 2026-04-29 - [S-3](https://www.sec.gov/Archives/edgar/data/1427925/000143774926009657/acrx20260324_s3.htm) filed 2026-03-25 - [10-K](https://www.sec.gov/Archives/edgar/data/1427925/000143774926009387/acrx20251231_10k.htm) filed 2026-03-23 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001427925), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Talphera, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TLPH, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Talphera, Inc. - **Ticker**: TLPH - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US00444T2096 - **Other listed symbols**: GETTEX:R5XA; LSX:A3DWPN - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TLPH/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/talphera/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Talphera (TLPH) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/talphera/